Enveric Biosciences, Inc. (ENVB)
1.39
-0.05
(-3.47%)
USD |
NASDAQ |
Sep 04, 16:00
1.39
0.00 (0.00%)
After-Hours: 20:00
Enveric Biosciences Research and Development Expense (Quarterly) : 1.355M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.355M |
| March 31, 2026 | 0.346M |
| December 31, 2025 | 0.3722M |
| September 30, 2025 | 0.4024M |
| June 30, 2025 | 1.260M |
| March 31, 2025 | 0.7464M |
| December 31, 2024 | 1.105M |
| September 30, 2024 | 0.7627M |
| June 30, 2024 | 0.5155M |
| March 31, 2024 | 0.4582M |
| December 31, 2023 | 1.369M |
| September 30, 2023 | 1.352M |
| June 30, 2023 | 2.513M |
| March 31, 2023 | 1.99M |
| December 31, 2022 | 1.893M |
| September 30, 2022 | 2.056M |
| June 30, 2022 | 2.120M |
| March 31, 2022 | 1.959M |
| December 31, 2021 | 2.493M |
| September 30, 2021 | 1.219M |
| June 30, 2021 | 0.8798M |
| March 31, 2021 | 0.158M |
| September 30, 2020 | 0.0633M |
| June 30, 2020 | 0.051M |
| March 31, 2020 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 0.00 |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 0.00 |
| Impact BioMedical, Inc. | 0.076M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |